Cargando…

Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin

INTRODUCTION: Studies have shown that achieving a time in therapeutic range (TTR) for warfarin of greater than 60% is associated with a lower risk of bleeding. However, many patients on hemodialysis (HD) do not achieve this target. METHODS: We audited TTR achievement at the in-center HD unit of our...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Daniel, Beaubien-Souligny, William, Battistella, Marisa, Tseng, Eric, Harel, Ziv, Nijjar, Jaspreet, Nazvitch, Elena, Silver, Samuel A., Wald, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000800/
https://www.ncbi.nlm.nih.gov/pubmed/32043029
http://dx.doi.org/10.1016/j.ekir.2019.10.011
_version_ 1783494112251478016
author Blum, Daniel
Beaubien-Souligny, William
Battistella, Marisa
Tseng, Eric
Harel, Ziv
Nijjar, Jaspreet
Nazvitch, Elena
Silver, Samuel A.
Wald, Ron
author_facet Blum, Daniel
Beaubien-Souligny, William
Battistella, Marisa
Tseng, Eric
Harel, Ziv
Nijjar, Jaspreet
Nazvitch, Elena
Silver, Samuel A.
Wald, Ron
author_sort Blum, Daniel
collection PubMed
description INTRODUCTION: Studies have shown that achieving a time in therapeutic range (TTR) for warfarin of greater than 60% is associated with a lower risk of bleeding. However, many patients on hemodialysis (HD) do not achieve this target. METHODS: We audited TTR achievement at the in-center HD unit of our hospital in 2017 and found that only 40% of patients had achieved a TTR >60%. We aimed to improve the percentage of HD patients achieving target TTR within 2 years. We reported each patient's individualized trend in quarterly TTR to their primary warfarin prescriber as an audit-feedback report. These reports were generated, disseminated, and subsequently improved following a series of plan-do-study-act cycles. We then used statistical process control to assess for changes in the percentage of HD patients achieving target TTR over time. RESULTS: In the primary analysis, 28 patients were included in the baseline period, and 46 were included in the intervention period. At baseline, the percentage of patients achieving a TTR >60% varied between 33% and 45% (mean ± SD, 40% ± 5%); post-intervention, this metric improved and varied between 52% and 71% (mean ± SD, 61% ± 8%). In time-series analysis, there was evidence of statistically significant variation between the 2 periods and evidence of sustained improvement. CONCLUSIONS: A quality improvement program consisting of an audit-feedback report that raises awareness of the quality gap in TTR achievement can result in substantial improvement in the safe and efficacious administration of warfarin to patients receiving maintenance hemodialysis.
format Online
Article
Text
id pubmed-7000800
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70008002020-02-10 Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin Blum, Daniel Beaubien-Souligny, William Battistella, Marisa Tseng, Eric Harel, Ziv Nijjar, Jaspreet Nazvitch, Elena Silver, Samuel A. Wald, Ron Kidney Int Rep Clinical Research INTRODUCTION: Studies have shown that achieving a time in therapeutic range (TTR) for warfarin of greater than 60% is associated with a lower risk of bleeding. However, many patients on hemodialysis (HD) do not achieve this target. METHODS: We audited TTR achievement at the in-center HD unit of our hospital in 2017 and found that only 40% of patients had achieved a TTR >60%. We aimed to improve the percentage of HD patients achieving target TTR within 2 years. We reported each patient's individualized trend in quarterly TTR to their primary warfarin prescriber as an audit-feedback report. These reports were generated, disseminated, and subsequently improved following a series of plan-do-study-act cycles. We then used statistical process control to assess for changes in the percentage of HD patients achieving target TTR over time. RESULTS: In the primary analysis, 28 patients were included in the baseline period, and 46 were included in the intervention period. At baseline, the percentage of patients achieving a TTR >60% varied between 33% and 45% (mean ± SD, 40% ± 5%); post-intervention, this metric improved and varied between 52% and 71% (mean ± SD, 61% ± 8%). In time-series analysis, there was evidence of statistically significant variation between the 2 periods and evidence of sustained improvement. CONCLUSIONS: A quality improvement program consisting of an audit-feedback report that raises awareness of the quality gap in TTR achievement can result in substantial improvement in the safe and efficacious administration of warfarin to patients receiving maintenance hemodialysis. Elsevier 2019-11-06 /pmc/articles/PMC7000800/ /pubmed/32043029 http://dx.doi.org/10.1016/j.ekir.2019.10.011 Text en © 2019 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Blum, Daniel
Beaubien-Souligny, William
Battistella, Marisa
Tseng, Eric
Harel, Ziv
Nijjar, Jaspreet
Nazvitch, Elena
Silver, Samuel A.
Wald, Ron
Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title_full Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title_fullStr Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title_full_unstemmed Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title_short Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
title_sort quality improvement program improves time in therapeutic range for hemodialysis recipients taking warfarin
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000800/
https://www.ncbi.nlm.nih.gov/pubmed/32043029
http://dx.doi.org/10.1016/j.ekir.2019.10.011
work_keys_str_mv AT blumdaniel qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT beaubiensoulignywilliam qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT battistellamarisa qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT tsengeric qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT harelziv qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT nijjarjaspreet qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT nazvitchelena qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT silversamuela qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin
AT waldron qualityimprovementprogramimprovestimeintherapeuticrangeforhemodialysisrecipientstakingwarfarin